NorthSea Raises Cash For NASH Program
Executive Summary
NorthSea raises €25m to push icosabutate, its only clinical compound, which was licensed from Pronova BioPharma, into Phase IIb trials for fatty liver disease. The drug has previously been tested in hypertriglyceridemia and dyslipidemia.
You may also be interested in...
Finance Watch: Billions Flow Into Biopharma Via Three New Investment Funds
Blackstone raised $3.44bn of a $4.58bn life science fund, while HealthCare Royalty Partners raised $1.8bn and MVM closed a $325m fund. Also, 20 private drug developers raised $20m or more, but three public biopharma firms unveiled restructuring plans.
New Cash Moves NorthSea Up In NASH
With two new US investors on board, NST is financed to complete a Phase IIb trial of icosabutate in non-alcoholic steatohepatitis.
In Vivo's Top M&A Of 2019: Cast Your Vote!
It is time for In Vivo's 12th annual Deals of the Year contest. We've selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners.
Need a specific report? 1000+ reports available
Buy Reports